The third one is deemed to have passed the consistency evaluation

On November 11, Kelun pharmaceutical announced that the company had recently obtained the approval document for drug registration of the chemical "apixaban tablets" approved and issued by the State Drug Administration, which was deemed to have passed the consistency evaluation This is the third enterprise in China to pass the consistency evaluation after hausen and Zhengda Tianqing Apixaban, originally developed as Bristol Myers Squibb and Pfizer, is mainly used in adult patients undergoing selective hip or knee replacement to prevent venous thromboembolism (VTE) Apixaban is a reversible and highly selective direct XA factor inhibitor, which belongs to a new type of oral anticoagulant Compared with other commonly used anticoagulants such as warfarin, apixaban has good safety and tolerance, wide treatment window, and can effectively reduce the incidence of cerebral apoplexy and systemic embolism without increasing the risk of bleeding It has less interaction with food, fixed dose, and no need for routine hematology monitoring, so it is more convenient to use Chinese expert guide for prevention and treatment of tumor related venous thromboembolism (2015 Edition), Chinese guide for prevention of surgical venous thromboembolism of orthopaedic University and other authoritative domestic guidelines recommend factor Xa inhibitor apixaban to prevent venous thromboembolism 37